Delivering gene therapies to the central nervous system presents a significant challenge due to the blood-brain barrier (BBB), which restricts the passage of therapeutic agents. Traditional methods for BBB opening can be invasive or lack the precision required for targeted delivery, limiting the efficacy and safety of CNS gene therapies.

Harmonix develops proprietary microbubbles designed for non-invasive, targeted gene therapy delivery to the central nervous system. Upon activation by focused ultrasound, these microbubbles facilitate reproducible and safe opening of the BBB, enabling efficient nucleic acid delivery to specific sites within the brain. This platform enhances gene expression, paving the way for advanced therapeutic applications in neurological disorders.

Patented formulation of cationic microbubbles for nucleic acid encapsulation.

Focused ultrasound activation for controlled and targeted BBB opening.

Non-invasive delivery mechanism for enhanced safety profile.

Demonstrated efficiency in nucleic acid transport across the BBB.

Supports enhanced gene expression at the site of ultrasound activation.

The primary target audience includes pharmaceutical companies and research institutions developing gene therapies for central nervous system disorders.